Qalabka tijaabada degdega ah ee Pepsinogen I Pepsinogen II iyo Gastrin-17 Combo
Qalabka Baadhista ee Pepsinogen I/Pepsinogen II /Gastrin-17
Habka: baaritaanka immunochromatographic fluorescence
Macluumaadka wax soo saarka
| Lambarka Moodeelka | G17/PGI/PGII | Baakad | 25 Tijaabo/xirmo, 30 xirmo/CTN |
| Magaca | Qalabka Baadhista ee Pepsinogen I/Pepsinogen II /Gastrin-17 | Kala soocidda qalabka | Fasalka II |
| Astaamaha | Xasaasiyadda Sare, Hawlgal Fudud | Shahaadada | CE/ ISO13485 |
| Saxnaanta | > 99% | Muddada khaanadaha | Laba Sano |
| Habka cilmi-baarista | Baaritaanka immunochromatographic ee fluorescence | Adeegga OEM/ODM | La heli karo |
ISTICMAALKA LOOGU TALAGALAY
Qalabkani wuxuu khuseeyaa ogaanshaha tirada ee ku jirta fiirsashada Pepsinogen I (PGI), Pepsinogen II ee in vitro
(PGII) iyo Gastrin 17 ee serum-ka aadanaha/balasma-da dhiigga oo dhan, si loo qiimeeyo unugyada qanjidhada oksaydhka caloosha
Shaqada, dhaawaca xuubka caloosha iyo caloosha iyo gastritis-ka atrophic. Qalabkani wuxuu bixiyaa oo keliya natiijada baaritaanka ee Pepsinogen I
(PGI), Pepsinogen II (PGII) iyo Gastrin 17. Natiijada la helay waa in lagu falanqeeyaa iyadoo lala kaashanayo kuwa kale ee kiliinikada.
Macluumaad. Waa inay isticmaalaan oo keliya xirfadlayaasha daryeelka caafimaadka.
Habka tijaabada
| 1 | Kahor intaadan isticmaalin daawada reagent-ka, si taxaddar leh u akhri baakadka ku jira oo baro hababka qalliinka. |
| 2 | Dooro qaabka tijaabada caadiga ah ee falanqeeyaha difaaca jirka ee la qaadi karo ee WIZ-A101. |
| 3 | Fur baakadda bacda aluminiumka ah ee reagent-ka oo soo saar qalabka tijaabada. |
| 4 | Si toosan ugu geli qalabka tijaabada godka falanqeeyaha difaaca jirka. |
| 5 | Bogga hore ee is-dhexgalka hawlgalka ee falanqeeyaha difaaca jirka, dhagsii "Standard" si aad u gasho is-dhexgalka tijaabada |
| 6 | Guji "QC Scan" si aad u sawirto koodka QR ee dhinaca gudaha ee xirmada; xuduudaha la xiriira xirmada gelinta ee qalabka iyo dooro nooca muunadda. Fiiro gaar ah: Lambar kasta oo dufcad ah oo ka mid ah qalabka waa in hal mar la iskaan gareeyaa. Haddii lambarka dufcadda la iskaan gareeyay, markaa Ka bood tallaabadan. |
| 7 | Hubi isku dheelitirka "Magaca Alaabta", "Lambarka Dufcadda" iwm. Isku-xirka tijaabada oo leh macluumaad ku saabsan qalabka calaamad. |
| 8 | Ka dib marka la xaqiijiyo isku dheelitirnaanta macluumaadka, soo saar walxaha milma muunadda, ku dar 80µL oo ah serum/plasma/dhiig dhan muunad, oo ku filan isku dar. |
| 9 | Ku dar 80µL oo ah xalka isku dhafan ee kor ku xusan godka muunadda ee qalabka tijaabada. |
| 10 | Ka dib marka aad dhammaystirto ku darista muunadda, dhagsii "Waqtiga" waqtiga imtixaanka ee harayna si toos ah ayaa loogu soo bandhigi doonaa is-dhexgalka. |
| 11 | Falanqeeyaha difaaca jirka ayaa si toos ah u dhammaystiri doona baaritaanka iyo falanqaynta marka la gaaro waqtiga baaritaanka. |
| 12 | Xisaabinta natiijada iyo muujinta Ka dib marka baaritaanka uu sameeyo falanqeeyaha difaaca jirka, natiijada baaritaanka waxaa lagu soo bandhigi doonaa is-dhexgalka tijaabada ama waa la daawan karaa iyada oo loo marayo "Taariikhda" bogga hore ee interface-ka hawlgalka. |
Waxqabadka Caafimaadka
Waxqabadka qiimaynta kiliinikada ee badeecada waxaa lagu qiimeeyaa iyadoo la ururinayo 200 oo muunado caafimaad ah. Isticmaal qalabka suuqgeynta ee tijaabada enzyme-ka ee isku xiran ee immunosorbent sida reagent-ka xakamaynta. Isbarbardhig natiijooyinka baaritaanka PGI. Isticmaal dib-u-celinta toosan si aad u baarto isbarbardhiggooda. Isu-dheellitirka isku xirnaanta ee laba imtixaan waa y = 0.964X + 10.382 iyo R=0.9763 siday u kala horreeyaan. Isbarbardhig natiijooyinka baaritaanka PGII. Isticmaal dib-u-celinta toosan si aad u baarto isbarbardhiggooda. Isu-dheellitirka isku xirnaanta ee laba imtixaan waa y = 1.002X + 0.025 iyo R=0.9848 siday u kala horreeyaan. Isbarbardhig natiijooyinka baaritaanka G-17. Isticmaal dib-u-celinta toosan si aad u baarto isbarbardhiggooda. Isu-dheellitirka isku xirnaanta ee laba imtixaan waa y = 0.983X + 0.079 iyo R=0.9864 siday u kala horreeyaan.
Waxa kale oo aad jeclaan kartaa:















